Key Takeaways
- • Forbion has closed €2.3 billion ($2.6 billion) across its latest venture and growth funds, establishing a new record for the European life sciences investor and surpassing the €2.09 billion raised for the predecessor pair two years prior.
- • The fundraise represents a significant capital commitment to European biotech innovation and positions Forbion as a major institutional allocator in the life sciences venture ecosystem.
- • The dual-fund structure—combining venture and growth capital—reflects Forbion's strategy to deploy capital across multiple stages of biotech company development.
Summary
Forbion, a prominent European life sciences investment firm, has successfully closed its latest funding round at €2.3 billion across two new venture and growth funds, marking a record deployment for the firm. The capital raise exceeds the €2.09 billion the firm collected for its predecessor funds approximately two years ago, demonstrating sustained and growing institutional demand for European biotech exposure.
The dual-fund strategy enables Forbion to support biotech companies across multiple development stages, from early-stage venture investments through growth-phase scaling. This approach has become increasingly prevalent among specialized life sciences investors seeking to capture value creation opportunities across the biotech investment spectrum.
The fundraise underscores continued institutional investor confidence in European biotech innovation despite macroeconomic headwinds affecting venture capital broadly. For limited partners seeking exposure to the European life sciences sector, Forbion's record close signals both the firm's track record and the perceived investment opportunity in continental European biotech ventures.
The dual-fund strategy enables Forbion to support biotech companies across multiple development stages, from early-stage venture investments through growth-phase scaling. This approach has become increasingly prevalent among specialized life sciences investors seeking to capture value creation opportunities across the biotech investment spectrum.
The fundraise underscores continued institutional investor confidence in European biotech innovation despite macroeconomic headwinds affecting venture capital broadly. For limited partners seeking exposure to the European life sciences sector, Forbion's record close signals both the firm's track record and the perceived investment opportunity in continental European biotech ventures.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.